Immunotherapy Emerging As Treatment For Lymphoma

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to fighting cancerous cells in precise ways.

Active immunotherapies trigger the body’s immune system to combat cancerous cells. Passive immunotherapies use immune system components like antibodies generated outside the body to fight tumors.

Now researchers at the Icahn School of Medicine at Mount Sinai Hospital are claiming that active and passive immunotherapies could hold the key to fighting lymphoma both now and in the future. This is especially true for passive therapies used to treat Hodgkin’s lymphoma - as standard immunotherapies have failed one-third of patients suffering from the disease.

“If these treatments are able to cure lymphoma, we would be delighted,” said Dr. Joshua Brody, director of the study.

Active versus passive

Researchers stated that active immunotherapies are already an industry standard for many forms of cancer. The treatments have shown promise during clinical trials in fighting hard-to-treat diffuse large cell lymphoma.

In fact, recent studies claim that patients who did not respond well to other treatments showed response rates of over 80 percent when receiving passive immunotherapies.

“If [the treatments] are effective, but not good enough to cure lymphoma, if they are able to push off a patient’s need for chemotherapy, or radiation therapy, or other standard therapies, that would still be pretty gratifying for some of our patients,” said Brody.

Source: Lymphoma News Today

More Articles

More Articles

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Sitemap